Voya Investment Management LLC Purchases 179,180 Shares of Intellia Therapeutics, Inc. $NTLA

Key Points

• Voya Investment Management LLC significantly increased its stake in Intellia Therapeutics by purchasing 179,180 shares, raising their ownership to approximately 0.20%, valued at $1.48 million.
• Analysts have shown mixed sentiments on Intellia Therapeutics, with price targets ranging from a high of $45.00 down to a low of $7.00, contributing to an average target of $27.39.
• Despite reporting a 104.3% year-over-year revenue increase to $14.25 million, Intellia posted a quarterly EPS of ($0.99), exceeding analysts' estimates.

Voya Investment Management LLC raised its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 621.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 208,009 shares of the company's stock after purchasing an additional 179,180 shares during the quarter. Voya Investment Management LLC owned approximately 0.20% of Intellia Therapeutics worth $1,479,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in NTLA. Millennium Management LLC lifted its holdings in Intellia Therapeutics by 190.5% during the 4th quarter. Millennium Management LLC now owns 668,926 shares of the company's stock valued at $7,800,000 after purchasing an additional 438,625 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Intellia Therapeutics by 38.0% in the fourth quarter. ProShare Advisors LLC now owns 33,404 shares of the company's stock worth $389,000 after purchasing an additional 9,196 shares during the period. Squarepoint Ops LLC grew its position in Intellia Therapeutics by 58.8% in the fourth quarter. Squarepoint Ops LLC now owns 101,417 shares of the company's stock valued at $1,183,000 after acquiring an additional 37,533 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Intellia Therapeutics by 5.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 483,185 shares of the company's stock valued at $5,634,000 after acquiring an additional 23,173 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in shares of Intellia Therapeutics in the 4th quarter valued at $25,000. Institutional investors and hedge funds own 88.77% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on NTLA shares. HC Wainwright boosted their price target on Intellia Therapeutics from $25.00 to $30.00 and gave the stock a "buy" rating in a report on Friday. Wells Fargo & Company reaffirmed an "overweight" rating and set a $45.00 target price (down from $50.00) on shares of Intellia Therapeutics in a research report on Friday, August 8th. JMP Securities reissued a "market perform" rating on shares of Intellia Therapeutics in a research report on Friday. Wedbush reaffirmed a "neutral" rating and set a $7.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 16th. Finally, Canaccord Genuity Group decreased their target price on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research report on Tuesday, June 3rd. Eleven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $27.39.

Insider Activity at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 7,462 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the sale, the executive vice president directly owned 106,062 shares of the company's stock, valued at $1,486,989.24. This represents a 6.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William J. Chase purchased 100,000 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, August 20th. The stock was purchased at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the purchase, the director owned 134,693 shares of the company's stock, valued at $1,350,970.79. This trade represents a 288.24% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 12,534 shares of company stock worth $153,837 over the last three months. Insiders own 3.10% of the company's stock.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $17.26 on Tuesday. The business's 50 day simple moving average is $11.94 and its two-hundred day simple moving average is $9.79. The stock has a market capitalization of $1.85 billion, a P/E ratio of -3.68 and a beta of 2.28. Intellia Therapeutics, Inc. has a one year low of $5.90 and a one year high of $21.94.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, topping analysts' consensus estimates of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The business had revenue of $14.25 million for the quarter, compared to analysts' expectations of $12.26 million. During the same period in the previous year, the firm earned ($1.52) EPS. The business's quarterly revenue was up 104.3% on a year-over-year basis. Sell-side analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.